116 related articles for article (PubMed ID: 34551565)
1. Review of tumor infiltrating lymphocytes assessment in breast cancer in routine diagnostic practice.
Dundr P; Gregová M; Bártů M; Zimovjanová M; Petruželka L; Bielčiková Z; Fabian P; Matěj R; Ryška A; Němejcová K
Cesk Patol; 2021; 57(3):161-166. PubMed ID: 34551565
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
4. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
5. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
7. Correlation between
Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y
Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248
[TBL] [Abstract][Full Text] [Related]
8. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
15. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Thagaard J; Broeckx G; Page DB; Jahangir CA; Verbandt S; Kos Z; Gupta R; Khiroya R; Abduljabbar K; Acosta Haab G; Acs B; Akturk G; Almeida JS; Alvarado-Cabrero I; Amgad M; Azmoudeh-Ardalan F; Badve S; Baharun NB; Balslev E; Bellolio ER; Bheemaraju V; Blenman KR; Botinelly Mendonça Fujimoto L; Bouchmaa N; Burgues O; Chardas A; Chon U Cheang M; Ciompi F; Cooper LA; Coosemans A; Corredor G; Dahl AB; Dantas Portela FL; Deman F; Demaria S; Doré Hansen J; Dudgeon SN; Ebstrup T; Elghazawy M; Fernandez-Martín C; Fox SB; Gallagher WM; Giltnane JM; Gnjatic S; Gonzalez-Ericsson PI; Grigoriadis A; Halama N; Hanna MG; Harbhajanka A; Hart SN; Hartman J; Hauberg S; Hewitt S; Hida AI; Horlings HM; Husain Z; Hytopoulos E; Irshad S; Janssen EA; Kahila M; Kataoka TR; Kawaguchi K; Kharidehal D; Khramtsov AI; Kiraz U; Kirtani P; Kodach LL; Korski K; Kovács A; Laenkholm AV; Lang-Schwarz C; Larsimont D; Lennerz JK; Lerousseau M; Li X; Ly A; Madabhushi A; Maley SK; Manur Narasimhamurthy V; Marks DK; McDonald ES; Mehrotra R; Michiels S; Minhas FUAA; Mittal S; Moore DA; Mushtaq S; Nighat H; Papathomas T; Penault-Llorca F; Perera RD; Pinard CJ; Pinto-Cardenas JC; Pruneri G; Pusztai L; Rahman A; Rajpoot NM; Rapoport BL; Rau TT; Reis-Filho JS; Ribeiro JM; Rimm D; Roslind A; Vincent-Salomon A; Salto-Tellez M; Saltz J; Sayed S; Scott E; Siziopikou KP; Sotiriou C; Stenzinger A; Sughayer MA; Sur D; Fineberg S; Symmans F; Tanaka S; Taxter T; Tejpar S; Teuwen J; Thompson EA; Tramm T; Tran WT; van der Laak J; van Diest PJ; Verghese GE; Viale G; Vieth M; Wahab N; Walter T; Waumans Y; Wen HY; Yang W; Yuan Y; Zin RM; Adams S; Bartlett J; Loibl S; Denkert C; Savas P; Loi S; Salgado R; Specht Stovgaard E
J Pathol; 2023 Aug; 260(5):498-513. PubMed ID: 37608772
[TBL] [Abstract][Full Text] [Related]
16. PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer.
Lusho S; Durando X; Bidet Y; Molnar I; Kossai M; Bernadach M; Lacrampe N; Veyssiere H; Cavaille M; Gay-Bellile M; Radosevic-Robin N; Abrial C
Medicine (Baltimore); 2020 Dec; 99(50):e23418. PubMed ID: 33327268
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
18. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J
BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
